3DPrint.com January 13, 2025
Pioneering solutions for metabolic and endocrine diseases, Vancouver-based Aspect Biosystems raised $115 million in Series B funding to advance its bioprinted tissue technology. Led by investment firm Dimension, the round included participation from existing and new investors like Novo Nordisk, Radical Ventures, Pangea Ventures, and Innovate BC. This brings Aspect Biosystems total to over $196 million in funding over 15 rounds.
The funds will help accelerate Aspect Biosystems’ development of treatments for diseases such as diabetes and obesity. This investment will also boost Aspect Biosystems’ platform, which combines AI-powered bioprinting, design tools, therapeutic cells, and biomaterials.
A New Frontier in Regenerative Medicine
Aspect Biosystems has been carving out a new category in regenerative medicine by working on bioprinted tissues to...
Today's Sponsors
Today's Sponsor